NCT00287820View on ClinicalTrials.gov

Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism

PHASE4CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

February 29, 2004

Study Completion Date

September 30, 2007

Conditions
SchizophreniaDiabetesMetabolic SyndromeHyperglycemia
Interventions
DRUG

Olanzapine

olanzapine 5-40 mg/day

DRUG

olanzapine

olanzapine 5-40 ,mg/day

DRUG

risperidone

risperidone 1-12 mg/day

Trial Locations (1)

10035

Manhattan Psychaitric Center, New York

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Nathan Kline Institute for Psychiatric Research

OTHER

NCT00287820 - Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism | Biotech Hunter | Biotech Hunter